Roll Over Study to Provide Idelalisib to Participants Previously Treated With the Investigational PI3Kδ Inhibitor, GS-9820

An Open Label, Roll Over Study to Provide Idelalisib to Subjects Previously Treated With the Investigational PI3Kδ Inhibitor, GS-9820

The primary objective of this study is to provide idelalisib to participants receiving GS-9820 in Gilead-sponsored Study GS-US-315-0102 at the time of study closure.

Key Inclusion Criteria:

• Receiving GS-9820 in Study GS-US-315-0102 with objective evidence of clinical benefit
• Evidence of a personally signed informed consent

Key Exclusion Criteria:

• Known hypersensitivity or intolerance to any of the active substances or excipients in the formulation of idelalisib
• Toxicities that would preclude initiating therapy with idelalisib prior to enrollment
• Concurrent participation in another therapeutic clinical trial
• Ongoing infection, treatment, or prophylaxis for cytomegalovirus (CMV) within the past 28 days.

Note: Other protocol defined Inclusion/ Exclusion criteria may apply.